| 0.0943 -0.04 (-29.63%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.16 |
1-year : | 0.19 |
| Resists | First : | 0.13 |
Second : | 0.16 |
| Pivot price | 0.13 |
|||
| Supports | First : | 0.08 |
Second : | 0.07 |
| MAs | MA(5) : | 0.12 |
MA(20) : | 0.13 |
| MA(100) : | 0.15 |
MA(250) : | 0.56 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 30 |
D(3) : | 35.9 |
| RSI | RSI(14): 25 |
|||
| 52-week | High : | 1.25 | Low : | 0.08 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ATXI ] has closed below the lower bollinger band by 24.8%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ATXI ] is to continue within current trading range. Bollinger Bands are 11.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.1 - 0.1 | 0.1 - 0.11 |
| Low: | 0.09 - 0.09 | 0.09 - 0.09 |
| Close: | 0.09 - 0.09 | 0.09 - 0.1 |
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
Wed, 24 Apr 2024
Why Avenue Therapeutics (ATXI) Shares Are Getting Hammered - Avenue Therapeutics (NASDAQ:ATXI) - Benzinga
Wed, 24 Apr 2024
Nasdaq Rises 0.5%; Tesla Shares Jump After Q1 Results - Amesite (NASDAQ:AMST), Avenue Therapeutics (NASDA - Benzinga
Wed, 24 Apr 2024
Avenue Therapeutics Announces Reverse Stock Split - GlobeNewswire
Tue, 19 Mar 2024
ATXI Stock Earnings: Avenue Therapeutics Beats EPS for Q4 2023 - InvestorPlace
Fri, 15 Mar 2024
Avenue Therapeutics gets Nasdaq listing extension By Investing.com - Investing.com
Fri, 15 Mar 2024
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 44 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 11.8 (%) |
| Held by Institutions | 2.7 (%) |
| Shares Short | 283 (K) |
| Shares Short P.Month | 163 (K) |
| EPS | -0.99 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.05 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -209.1 % |
| Return on Equity (ttm) | -535.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -76.4 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.1 |
| PEG Ratio | 0 |
| Price to Book value | 1.57 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.45 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|